Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Debbie Rigby 12/09/2023

Debbie Rigby takes a look at the latest in research news Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce elevated blood glucose levels and induce weight loss. Randomised trials support the superior efficacy of semaglutide over other GLP-1 RAs

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.